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Abstract The ability to diagnose cancer rapidly with
high sensitivity and specificity is essential to exploit
advances in new treatments to lead significant reductions in
mortality and morbidity. Current cancer diagnostic tests
observing tissue architecture and specific protein expres-
sion for specific cancers suffer from inter-observer vari-
ability, poor detection rates and occur when the patient is
symptomatic. A new method for the detection of cancer
using 1 ll of human serum, attenuated total reflection—
Fourier transform infrared spectroscopy and pattern
recognition algorithms is reported using a 433 patient
dataset (3897 spectra). To the best of our knowledge, we
present the largest study on serum mid-infrared spec-
troscopy for cancer research. We achieve optimum sensi-
tivities and specificities using a Radial Basis Function
Support Vector Machine of between 80.0 and 100 % for all
strata and identify the major spectral features, hence bio-
chemical components, responsible for the discrimination
within each stratum. We assess feature fed-SVM analysis
for our cancer versus non-cancer model and achieve 91.5
and 83.0 % sensitivity and specificity respectively. We
demonstrate the use of infrared light to provide a spectral
signature from human serum to detect, for the first time,
cancer versus non-cancer, metastatic cancer versus organ
confined, brain cancer severity and the organ of origin of
metastatic disease from the same sample enabling stratified
diagnostics depending upon the clinical question asked.
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Introduction
Attenuated total reflection—Fourier transform infrared
spectroscopy is rapid, cost-effective, simple to operate and
can be handheld. Biomolecules exhibit responses to dif-
ferent wavelengths of light, the resulting spectrum can be
thought of as the sample ‘fingerprint’, spectroscopic anal-
ysis allows for objective classification on a molecular level
[1]. ATR-FTIR is an excellent vibrational spectroscopic
technique for the analysis of biofluids (e.g. serum) due to
its rapidity and ease of translation to the clinical environ-
ment, i.e. ATR-FTIR requires no sample preparation when
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analysing serum [2]. During ATR-FTIR the infrared light is
directed through an internal reflection element (IRE) with a
high refractive index (e.g. diamond/germanium) enabling
an evanescent-wave to extend beyond the IRE surface
penetrating the sample, which must be in intimate contact
with the IRE surface [2]. A rapid spectroscopic serum-
screening regime would significantly reduce current diag-
nosis times and greatly increase the chance of successful
treatments [3–4]. Blood serum is a primary carrier of small
molecules in the body; it holds all secreted molecules from
different tissues in response to different physiological
needs, dysfunctions and pathological states [5].
Currently, in the UK, 38 % of people living with a brain
tumour visited their GP more than five times before being
diagnosed [6]. In addition, 23 % of newly diagnosed cancer
patients came from emergency presentations, with 1 year
survival rates much lower than those diagnosed via other
routes [6].Current diagnosis relies upon time consuming
and subjective histopathological examination. Diagnostic
error occurs in up to 50 % of cases, which can result in
additional testing, diagnostic delays and incorrect diag-
noses [7]. Prior to diagnosis the patient will have to be
symptomatic in order to be referred. Metastatic brain dis-
eases are the most common form of intracranial neoplasm
in adults and are predicted to develop in 20–40 % of cancer
patients [8]. Identifying the primary site of origin increased
the therapeutic success, however, in approximately 15 %
of metastatic cancer cases the location of the primary is
unknown [8]. Blood is the most ubiquitous fluid used for
diagnosis. Most current blood tests detect single biomark-
ers that are of limited suitability for screening [9], as cancer
is a heterogeneous disease a set of markers would provide
significantly more information that any one marker.
Previous spectroscopic research has provided evidence
of the benefits of applying spectroscopy to clinical prob-
lems [8, 10], and recently to the spectroscopic diagnosis of
diseases via biofluid analysis [11–12]. We have shown the
potential of ATR-FTIR spectroscopy for the rapid diag-
nosis of brain tumour severity using a 1 ll volume of
patient serum and within 10 min enabling diagnosis of high
grade glioma, low grade glioma and non-cancer with
severities and specificities on average of 93.75 and
96.53 % respectively [11–12]. Ollesch et al. have devel-
oped a robotic spotting system in combination with vac-
uum drying for the application of blood-derived substances
which would offer the ability of rapid screening [13].
A number of studies assess the role of spectroscopy for
the diagnosis of disease. Owens et al. successfully dis-
criminated between patients with ovarian cancer and non-
cancer using blood serum and plasma with Raman and
ATR-FTIR spectroscopy [14]. Gajjar et al. has shown the
ability of ATR-FTIR to differentiate between patients
diagnosed with either ovarian or endometrial cancer from
non-cancer controls using blood serum samples. Classifi-
cation results were as high as 96.7 % for ovarian cancer
and 81.7 % for endometrial cancer [15]. Backhaus et al.
distinguished between breast cancer serum and non-cancer
controls achieving a sensitivity and specificity of 98 and
95 % respectively [16].
This study reports, for the first time, the ability to pro-
vide stratified multiple diagnoses from human serum to
greatly enhance the capability and information obtained for
a simple, effective, reproducible and repeatable technique.
We report the application of ATR-FTIR spectroscopy for
stratified serum spectroscopic diagnostics capable of
diagnosing at different levels; from general cancer versus
non-cancer, metastatic cancer versus primary brain cancer,
glioma versus meningioma, the severity of the tumour
(high-grade glioma vs. low-grade glioma) and the organ of
origin of brain metastases using only 1 ll of a patient
serum sample and within 10 min of serum application. This
will provide a rapid diagnostic process capable of
deployment in situ from primary to tertiary care systems
depending upon the information required by different
clinical settings.
Materials and methods
Serum samples
Blood samples were collected from 433 patients over the
range of cancer groups analysed. Table 1 provides demo-
graphic information based on cancer group. The average
age is 57.77 and 44.77 years for the cancer and non-cancer
patient sample sets, respectively. Full sample data can be
found in supplementary information Table S2. The
research described in this paper was performed with full
ethical approval (Walton Research Bank BTNW/WRTB
13_01/BTNW Application #1108). All blood samples were
collected pre-operatively. The serum tubes were left to clot
at room temperature for a minimum of 30 min and maxi-
mum of 2 h from blood draw to centrifugation. Separation
of the clot was accomplished by centrifugation at 1,200 g
for 10 min and 500 ll aliquots of serum dispensed. All
serum samples were snap frozen using liquid nitrogen and
stored at -80 C. S1 shows a flow diagram of the analysis
and pre-processing steps, including which patient samples
are in each classification. Non-cancer (control) serum
samples were collected from individuals who presented no
symptoms of cancer at a Royal Preston Hospital (UK)
blood donation event, as well as those presenting to the
clinic for elective surgery.
We previously investigated the reproducibility of the
serum spectrum and the length of time required for a
reproducible spectrum to be obtained from a 1 ll volume
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of whole serum. At room temperature, 1 ll of serum has
been found to dry after 8 min through repeat drying
experiments. The reproducibility of serum spectral data
using ATR-FTIR is high and exhibits minimal variance,
especially after pre-processing, for 150 spectra collected
from 50 different human pool serum spots (3 spectral
repeats per spot). We found that the largest variance of the
ATR-FTIR spectrum was at 1637.27 cm-1 with a standard
deviation (STD) of 0.0050 and the smallest variance at
3735.33 cm-1 with a STD of 0.0038 from 150 collected
spectra. After noise reduction (30 principal components)
and vector normalization these STD values were reduced to
0.0043 and 0.00123 respectively [12].
Instrumentation
All spectra were collected using an Agilent Cary-600
Series FTIR spectrometer with a PIKE Technologies
MIRacleTM single-reflection ATR configured with a dia-
mond (Di) crystal plate. 1 ll volumes of human serum
were pipetted onto the ATR-FTIR crystal using an
Eppendorf Research-Plus 0.5–10.0 ul pipette. After spec-
tral collection from each 1 ll dried serum spot, Virkon
disinfectant (fisher-scientific) and 99.5 % ethanol (thermo-
scientific) were used consecutively to remove the serum
film from the crystal.
ATR-FTIR diagnostic model
All whole serum samples were thawed prior to spectral
collection at room temperature. Spectra were collected in a
random order within the serum sample sets. For each
sample, a 1 ll serum spot was pipetted onto the ATR-FTIR
crystal and allowed to dry for 8 min, at which time three
spectra were collected. Prior to spectral collection, a
background absorption spectrum was collected (for atmo-
spheric correction) before the 1 ll of serum was pipetted
onto the ATR-FTIR crystal. A single background was
collected per sample replicate. Spectra were acquired in the
range of 4000–600 cm-1, at a resolution of 4 cm-1 and
averaged over 32 co-added scans. In total, 3897 ATR-FTIR
spectra were collected from all serum samples.
Data handling and analysis
Initially agilent’s resolutions-pro FTIR software was used
for data handling after which the spectra were imported for
further analysis and processing into MatlabTM using in–
house written and open source protocols.
For all spectra acquired, the fingerprint region
(1800–1000 cm-1) was selected for multivariate analysis.
A principal component based noise reduction, using the
first 50 principal components of the data was performed on
the spectra to improve the signal-to-noise ratio. Following
noise reduction, all spectra were vector normalised. Using
LIBSVM and in-house written protocols [www.csie.ntu.
edu.tw/*cjlin/libsvm] in MATLABTM, an n-fold cross
validation was performed (n = 5) on the training data to
determine the optimum values for the cost and gamma
functions. Supplementary information S3 shows the opti-
mum cost and gamma functions for each stratum (e.g.
cancer vs. non-cancer). The optimum cost and gamma
values were used to train the support vector machine
(SVM) in a one-versus-rest mode using a randomly
selected training set consisting of 2/3 of the patient asso-
ciated spectral data. The remainder of the data (1/3) was
used to create the test set which was then projected into the
model, and confusion matrices were calculated giving an
overall SVM classification based on the true and predicted
data class labels. For each stratum 525 combinations of 2/3
training and 1/3 test were performed based upon patient
membership, thus, all spectra from one patient was either in
the train set or the test set. Sensitivities and specificities
were calculated for each combination in order to under-
stand the effect of patient membership in test and training
sets based upon sensitivity and specificity.
Table 1 Total subject number
of tumour grade, age range,
mean age and gender of patient
samples
Tumour grade Number of subjects Age range/mean age Gender
Non-cancer 122 16–89/44.77 years 64 Male, 58 female
All cancer 311 19–82/57.77 years 133 Male, 178 female
Glioma 87 19–81/49.90 years 52 Male, 35 female
Low-grade glioma 23 19–60/38.35 years 11 Male, 12 female
High-grade glioma 64 25–81/61.44 years 41 Male, 23 female
Meningioma 47 24–78/55.98 years 13 Male, 34 female
Metastasis 177 25–82/59.45 years 68 Male, 109 female
Lung metastasis 84 25–82/59.32 years 36 Male, 48 female
Breast metastasis 36 27–76/50.92 years 0 Male, 36 female
Melanoma Metastasis 25 25–80/56.00 years 14 Male, 11 female
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Feature extraction
The main function of feature extraction is to elucidate and
rank the relevant discriminatory spectral information from
recorded ATR-FTIR data. Per stratum, all pre-processed
spectral data were variably ranked (30 %) with information
gain. Variable ranking highlights the wavenumber vari-
ables that are most salient between the spectral classes. In
the case of the cancer versus non-cancer stratum, 130
wavenumber variables associated to six spectral regions
were selected (Table 4). Following variable ranking, the
ranked wavenumber regions were user selected on a 2D
plot of the mean spectrum, upon which feature extraction
(FE) was performed. FE was performed whereby spectral
descriptors such as RMS energy, peak kurtosis, peak skew,
peak centroid, peak frequency and peak amplitude can be
extracted from each user selected spectral band, thus the
relevant spectral band shapes involved in the discrimina-
tion between classes are able to be captured. The feature
information is ranked and scored in descending order to
describe how each feature of the model explains the dif-
ference between the groups of recorded spectral data. The
most discriminatory features highlighted during feature
extraction were then used for a feature based SVM (FE-
SVM). Using LIBSVM and in house written protocols
[www.csie.ntu.edu.tw/*cjlin/libsvm] in MATLABTM, an
n-fold cross validation was performed (n = 5) on the
cancer versus non-cancer spectral training data to deter-
mine the optimum values for the cost and gamma func-
tions. FE-SVM was performed using all 130 spectral
features followed by the top 30 and top 2 features for the
cancer versus non-cancer data set.
Sensitivity and Specificity
Sensitivity and specificity were calculated using Eqs. 1 and
2 respectively:
Sensitivity ¼ True Positives
True Positivesþ False Negatives ð1Þ
Specificity ¼ True Negatives
True Negativesþ False Positives ð2Þ
where,True Positives is the a patient with the target disease
has five or more spectra out of the nine spectra collected
from three different serum spots (three spectra per spot)
correctly identified.
True Negatives is the a patient without the target disease
who has five or more spectra out of the nine spectra col-
lected from three different serum spots (three spectra per
spot) correctly identified.
False Positives is the a patient without the target disease
who has five or more spectra out of the nine spectra
collected from three different serum spots (three spectra
per spot) that have been incorrectly identified as the target
disease.
False Negatives is the a patient with the target disease
who has five or more spectra out of the nine spectra col-
lected from three different serum spots (three spectra per
spot) that have been incorrectly classified as not the target
disease.
Kappa values
Kappa values were calculated using Eq. 3:
K ¼ ðpo  peÞð1 peÞ ð3Þ
where, K is the Kappa Value, Po is the observed agreement,
Pe is the expected agreement (chance agreement), po and pe
were calculated using Eqs. 4 and 5 respectively
ðTPþ TNÞ
ðTPþ TN þ FPþ FNÞ ð4Þ
TPþ FP=SUM ALL
 
 TPþ FN=SUM ALL
 h i
þ FN þ TN=SUM ALL
 
 FPþ TN=SUM ALL
 h i
ð5Þ
where, TP is the true positives, TN is the true negatives, FP
is the false positives, FN is the false negatives, SUM ALL
is the TP ? TN ? FP ? FN.
Using a patient based spectral diagnosis (correct clas-
sification of at least five out of nine spectra from three
different patient serum spots) when compared to clinical
diagnosis of that patient following a multidisciplinary team
(MDT) meeting.
Results and discussion
Rapid stratified serum spectroscopic diagnostics
ATR-FTIR spectra from 433 patients (3897 spectra) were
analysed to investigate sensitivities and specificities pos-
sible on a patient level. 525 iterations with different
training and test spectral datasets (split 1/3 test and 2/3
training on a patient basis) were used to analyze the power
of the RBF-SVM analysis. Supplementary information S4
displays a histogram of the range of sensitivities and
specificities achieved for the cancer versus non-cancer
stratum (histograms for all other strata are displayed in
supplementary information S5). The sensitivity and speci-
ficity range for cancer versus non-cancer is 81–97 % and
51–95 % respectively with sensitivity and specificity ran-
ges of 46–80 % and 60–93 % respectively for metastatic
466 J Neurooncol (2016) 127:463–472
123
cancer versus brain cancer, 48–100 % and 31–100 %
respectively for glioma versus meningioma, 50–100 % and
2–100 % respectively for high-grade glioma versus low-
grade glioma and 28–95 % and 68–98 % for the metastatic
origin stratum. Table 2 shows the mean, mode and opti-
mum sensitivities and specificities for each stratum. The
optimum sensitivity and specificity is the sensitivity and
specificity that best describes the sample set based upon
disease grouping.
The optimum, mode and mean sensitivities and speci-
ficities observed for all strata range from 51.4 to 100 %
respectively, with the optimum sensitivities and specifici-
ties achieving 86.3–100 %. The cancer versus non-cancer
stratum achieved a mean sensitivity and specificity of 89.8
and 77.5 % respectively, metastatic cancer versus brain
cancer of 79.7 and 64.0 % respectively, glioma versus
meningioma of 66.7 and 82.1 % respectively, high grade
glioma versus low grade glioma of 80.9 and 48.5 %
respectively and the origin of metastasis of 64.8 and
86.9 % respectively.
These results show the power of ATR-FTIR spec-
troscopy to diagnose disease states based upon a stratified
approach; however variance still exists in the spectral
datasets due to the selection of patient populations in the
test and training set. For each stratum, sensitivity and
specificity variance exists between classification model
iterations. This shows that certain patient partitions provide
better classification for the remaining test patient data set.
A reason for this is redundant data maximizing the spectral
variance within a group within the data variables of the
spectral fingerprint region i.e. patient data containing
higher intra-group spectral variance partitioned together to
form the training set would produce poorer classification
models.
Feature extraction for stratified serum spectroscopic
diagnostics
To maximize classification accuracy the most salient fea-
tures of a spectrum can be extracted and ranked based on
their similarity to a target set, thus assigning scores on the
feature’s ability to discriminate between classes, maxi-
mizing inter-group differences [17].The spectral features
used are the peak centroid (measure of the peak’s central
point), peak skew (measure of asymmetry in the peak’s
shape), peak kurtosis (a measure of the shape of a peak
relating peaked vs. flat-topped), peak amplitude and root-
mean-squared (RMS) energy. These features were extrac-
ted from pre-defined sub-bands of each spectrum and the
corresponding inter-band ratios between features were then
ranked, using the information gain metric, based upon the
resulting score.
Following feature extraction and variable ranking the
most discriminatory characteristics of the spectrum (from
1800 to 900 cm-1) were extracted (Table 3 displays the
most discriminatory regions with proposed biomolecular
assignments) highlighting spectral components relating to
proteins, lipids, carbohydrates and nuclear material.
Interestingly the features observed for the 2-class strata,
enabling classification of cancer versus non-cancer,
Table 2 Mean, mode and optimum sensitivities and specificities obtained for each stratum
Model Optimum
sensitivity (%)
Optimum
specificity (%)
Mean
sensitivity
(%)
Mean
specificity
(%)
Mode
sensitivity
(%)
Mode
specificity
(%)
Cancer versus non-cancer 97.1 95.1 89.8 77.5 89.4 78.0
Metastatic cancer versus brain cancer 80.0 93.2 79.7 64.0 64.4 80.0
Glioma versus meningioma 100.0 100.0 81.1 66.7 82.1 75.0
High grade glioma (HGG) versus low
grade glioma (LGG)
100.0 100.0 80.9 48.5 85.0 50.0
Metastatic model Optimum
sensitivity (%)
Optimum
specificity (%)
Mean sensitivity
(%)
Mean specificity
(%)
Mode sensitivity
(%)
Mode specificity
(%)
Metastatic lung
cancer
95.4 95.9 79.0 85.7 81.4 84.9
Metastatic skin
cancer
84.4 94.4 63.9 82.0 64.4 80.3
Metastatic breast
cancer
78.6 98.9 51.4 90.1 50.0 90.9
Metastatic model
mean
86.3 98.3 64.8 86.0 65.3 85.4
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metastatic versus brain cancer, glioma versus meningioma
and high-grade glioma versus low-grade glioma (top 10
features for each 2-class stratum are displayed in supple-
mentary information S6) which focus on the detection and
diagnosis of primary brain cancer are originating from the
Amide I (vibrations originating from a–helix structures, b-
pleated sheets, turns and random coil (mC = O (80 %),
mC–N (10 %), CNN (10 %)) [18] and Amide II—vibra-
tions originating from a–helix structures, b-pleated sheets,
turns and random coil [d N–H (60 %), m C–N (40 %)], C–
O stretch of lipids/proteins, CH2 of lipids/proteins and
contributions from nuclear materials (DNA/RNA via PO2
-
stretches) spectral regions [18–27]. These spectral regions
have been described previously in research discriminating
between brain cancer states using tissue spectroscopy [22,
25]. The former highlighted the Amide I (1655 cm-1),
Amide II (1547 and 1582 cm-1), carbohydrate
(1173 cm-1), glycogen (1014 cm-1) and phosphate
regions as describing the majority of difference between
infrared spectra of tissue origination from non-cancerous
patients and tumour subtypes.
The features observed for the metastatic stratum (top 10
features for each primary site displayed in supplementary
information S7), enabling discrimination between the
organs of origin of the metastatic cancer (lung vs. mela-
noma vs. breast), focusing upon secondary brain tumours
are originating from vibrations of C–O, C=O and C–H
associated with lipids and protein macromolecules, con-
tributions associated with nucleic material (DNA/RNA via
PO2
-) and minimal contributions from the Amide spectral
regions. This correlates with research performed by Gazi
et al. [23, 24] when utilizing FTIR microscopy to investi-
gate discrimination of metastatic prostate cancer tissue and
organ confined prostate cancer. Gazi et al. show increases
in biomolecular intensities of carbohydrate, phosphate and
lipid hydrocarbon intensities between organ confined
prostate cancer and prostate cancer bone metastases tissue
specimens. Krafft et al. highlight spectral features at 1026,
1080 and 1153 cm-1 as molecular markers for brain
metastases of the primary tumour renal cell carcinoma, the
intensity at 1735 cm-1, assigned to the carbonyl vibrations
(C=O) of ester groups as indicative of brain metastases of
breast cancer, an increase in Amide II intensity and
broadening of the Amide I low wavenumber shoulder near
1625 cm-1 for brain metastases of lung cancer and an
intensity minimum near 1400 cm-1 for brain metastases of
colorectal cancer when performing IR spectroscopic
imaging of brain tissue [25]. The similar regions observed
for the tissue spectroscopic studies as compared to serum
based spectroscopic studies provide corroborating evidence
or the power of the analysis as the serum biochemical
profile is understood to reflect the tissue status.
In order to examine the ability of feature extraction to
improve the diagnostic capability of stratified serum diag-
nostics a 525 iteration feature-fed SVM was performed
using all of the 130 features discovered during the feature
extraction process, the top 30 features and the top 2 fea-
tures for the cancer versus non-cancer stratum, based on a
variable ranking process. All 130 features are displayed in
supplementary information Table S8. Highlighting the
spectral regions described previously.
Supplementary information S9 displays the histograms
showing the sensitivity and specificities achieved when
analysing 525 iterations of a 130 feature-fed SVM (A), 30
feature-fed SVM (B) and 2 feature-fed SVM (C) for the
cancer versus non-cancer stratum. When compared to the
full fingerprint region SVM shown in supplementary
information S3 the range of sensitivities and specificities
observed achieve higher percentages and occur over a
smaller range, when compared to the SVM analysis of data
from the full spectral fingerprint region, from 81 to 97 %
and 51–95 % respectively for -the fingerprint region SVM
and from 82 to 98 % and 66–97 % respectively for the 130
feature-fed SVM, 81–98 % and 66–95 % for the top 30
feature-fed SVM respectively and 81–96 % and 51–95 %
for the top 2 feature-fed SVM respectively.
The mode sensitivity and specificity for the full finger-
print region SVM of the cancer versus non-cancer stratum
was 89.4 and 78.0 % respectively compared to mode sen-
sitivities and specificities of 92.3 and 80.5 % when using
Table 3 Discriminatory spectral regions with biomolecular assignments
Wavenumber region (cm-1) Assignments
1008–1230 C–O stretch, deoxyribose/ribose, DNA, RNA (PO2
-), C–C stretch, C–H bend
1315–1384 CH3/CH2 bending
1380–1465 CH3 lipids/proteins and COO
- of amino acids
1460–1590 Amide II of proteins (a—helix structures, b—pleated sheet structures, turns, random coils),
d N–H (60 %), m C–N (40 %)
1600–1706 Amide I of proteins (a—helix structures, b—pleated sheet structures, turns, random coils),
m C=O (76 %), m C–N (14 %), CNN (10 %)
1700–1799 d C=O of lipids
468 J Neurooncol (2016) 127:463–472
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130 spectral features. The top 30 features achieved 91.3
and 82.9 % when using 30 features and 89.4 and 70.7 %
when using 2 spectral features (Table 4). The mean sen-
sitivity and specificity for the feature extracted models
follows the same trend with all 130 features achieving
91.5 % sensitivity and 83.0 % specificity, 30 features
achieving 90.6 % sensitivity and 81.9 % specificity and 2
features achieving 88.7 % sensitivity and 77.7 % speci-
ficity. The mean sensitivities and specificities achieved
using full fingerprint region SVM are similar to those that
can be achieved using the top 2 spectral features of 89.8 %
sensitivity and 77.5 % specificity. The top 2 spectral fea-
tures that describe the differences between the cancer
versus non-cancer disease groupings are RMS energy of
C-O groups, PO2
-, RNA/DNA (1176–1242 cm-1) versus
vibrations PO2
- stretch of nucleic acids, RNA/DNA
(1020–1115 cm-1) and the skew of the C-O groups, PO2
-,
RNA/DNA (1176–1242 cm-1) versus the CH2 of lipids/
proteins and Amide II (1483–1537 cm-1) [18–27].
We achieved the optimum sensitivities and specificities
from our model consisting of all 130 spectral features for
cancer versus non-cancer. Features are ranked in order of
how representative they are of the original data, thus a
reduction in the diagnostic ability from 2 spectral features,
compared to all 130 or top 30, is not surprising due to the
reduction in spectral information available during feature-
fed-SVM.
The ability to select and rank spectral features enables
the extraction of data that describes the differences within
the disease groupings without addition of added variance
based upon other contributing factors from the patients and
enables biochemical differences, via spectral peaks, to be
observed whereas a full spectral SVM does not. In addi-
tion, the selection of spectral features, based upon the
collection of the full FTIR spectrum, allows for targeting of
the most discriminatory regions during a sparse frequency
collection approach [28, 29], and reduction in the pro-
cessing power required for classification of disease states
providing a quicker and more efficient spectroscopic
diagnostic process.
Clinical impact
Vibrational spectroscopy can provide rapid, label-free and
objective analysis for clinical practice [26, 27]. This proof
of principle project provides substantial translational lab-
oratory research to enable the development of clinical
serum spectroscopic diagnostics. The rapidity, ease-of-use,
low sample volume, reproducibility and detection charac-
teristics shown by this methodology would provide for a
rapid and responsive diagnostic tool that can be used
throughout the patient pathway [28]. As such the potential
clinical impact of serum spectroscopic diagnostics for brain
tumours can be:
(1) Robust, rapid diagnostic test with high sensitivity
and specificity that can distinguish brain tumours
from non cancerous disease prompting more timely
onward referral of patients for further testing
(2) A test capable of monitoring response to treatment
(surgery, radiotherapy, chemotherapy) and detection
of recurrent disease enabling serial sample and
testing with less cost, resource and radiation expo-
sure compared to conventional methods. In addition
such a test may overcome the time lag required to
observe changes in tumour size and characteristics
on MRI.
Kappa values
In order to understand the reliability of a diagnostic model
the Kappa value is used to assess the inter-observer
agreement whilst correcting for chance (see Materials and
Methods), where a Kappa value of\0 indicates a less than
chance agreement, 0.01–0.20 slight agreement, 0.21–0.40
fair agreement, 0.41–0.60 moderate agreement, 0.61–0.80
substantial agreement and 0.8–1.00 almost perfect agree-
ment [30]. Figure 1 shows Kappa values from a range of
currently used diagnostic tests and proposed spectroscopic
diagnoses.
Figure 1 shows a Kappa value of 0.12(A) when com-
paring the histopathological diagnosis of glioblastoma of
34 patients between local, institutional and central neuro-
oncopathology reporting concluding that concordance was
sub-optimal when comparing local and central review,
however the Kappa value did increase to moderate agree-
ment (k = 0.51) when comparing institutional and central
review [31]. For mammography(B, D, F, G) a review of 31
community radiologists concerning 30 women with cancer
and 83 without was undertaken to assess the advantages of
Table 4 Optimum, mean and mode sensitivities and specificities for the cancer versus non-cancer stratum using 130, 30 and 2 spectral features
Model Optimum
sensitivity (%)
Optimum
specificity (%)
Mean
sensitivity (%)
Mean
specificity (%)
Mode
sensitivity (%)
Mode
specificity (%)
All 130 features 98.1 97.6 91.5 83.0 92.3 80.5
Top 30 features 98.1 95.1 90.6 81.9 91.3 82.9
Top 2 features 96.2 95.1 88.7 77.7 89.4 70.7
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single versus double interpretation comparing the Kappa
values from 465 pairs of radiologist and 31,465 pairs of
unique pairs. The mean Kappa values for identify non-
cancer radiologist when diagnosing non-cancer was
0.30(B) for single interpretation increasing to 0.34(C) on
double interpretation and for cancer was 0.59(F) for single
interpretation increasing to 0.70(G) for double interpreta-
tion [32]. The correlation between Gleason score at biopsy
and prostatectomy of 371 patients undergoing radical
prostatectomy revealed a Kappa value of 0.42(D) based
upon prostate cancer histopathology concluding that this
concordance lies within classical clinical standards [33]
and a peer review assessment of 1086 abnormal cervical
smears evaluating laboratory cytology performance
achieved an overall Kappa value of 0.62(H) when assessing
10 cytologists diagnoses [34]. The Kappa values above are
derived from tests that require interpretation from tissue
architecture or other diagnostic markers showing a range of
Kappa values from 0.12 to 0.70 for these currently used
diagnostic tests. It is also interesting to consider a risk
factor based test that is performed within the primary care
centre in order to direct future treatment and patient care.
Examples of such measures are the Framingham Risk
Score (FRS) and the European Systemic Coronary Risk
Evaluation (SCORE) system for assessing high
cardiovascular risk. FRS is widely used within the USA
and SCORE is widely used throughout Europe, when
comparing the diagnosis of SCORE against that of FRS a
Kappa value of 0.42 equating to moderate agreement was
achieved [35]. As can be seen from this literature analysis
there exists a range of Kappa values from slight agreement
to substantial agreement for currently used diagnostic
procedures. Kendall et al. used Raman spectroscopy to
identify and classify neoplasia in Barrett’s oesophagus
when analysing tissue in vitro, in a study utilizing three
pathologists to provide a consensus opinion the Kappa
value using Raman spectroscopy achieved 0.89(I) [36]. The
Kappa values for the ATR-FTIR (J-N) stratified serum
diagnostic tests show similar high levels of agreement
when comparing against the diagnosis provided following a
multidisciplinary team meeting. For cancer versus non-
cancer(J) Kappa = 0.77, metastatic versus brain
cancer(K) Kappa = 0.90, glioma versus menin-
gioma(L) Kappa = 0.79, high grade Glioma versus low
grade Glioma (M) Kappa = 0.70 and the average meta-
static model(N) Kappa = 0.74 (lung Kappa = 0.81, skin
Kappa = 0.67 and breast Kappa = 0.75). All strata within
the stratified serum diagnostics approach showed Kappa
values in the substantial and almost perfect agreement
ranges.
Fig. 1 Kappa values for a range of currently used diagnostic tests and
proposed spectroscopic diagnoses (A) comparing the histological
diagnosis of glioblastoma between local, institutional and central
neuro-oncopathology reporting, (B and C) mean Kappa values for
breast mammograms using single and double interpretations for non-
cancer diagnosis, (D) correlation between Gleason score on biopsy
and following prostatectomy, (E) correlation between two commonly
used CV risk algorithms Framingham Risk Score (FRS) and European
Systemic Coronary Risk Evaluation System (SCORE) compared, (F
and G) mean Kappa values for breast mammograms using single and
double interpretations for cancer diagnosis, (H) peer review of
abnormal cervical smears, (I) Raman spectral prediction of Barrett’s
neoplasia in vitro compared to consensus pathology opinion (n = 3
pathologists), (J-N) Kappa values for ATR-FTIR spectroscopic
diagnosis based upon optimum sensitivity models over all strata
when comparing against clinical diagnosis following multidisci-
plinary team (MDT) meeting
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Conclusions
The stratified diagnostic methodology discussed has the
potential to be intertwined with current healthcare proto-
cols to benefit patient outcomes through early cancer
diagnosis. Blood is routinely collected from patients for
diagnostic and monitoring purposes, creating no require-
ment for dedicated sample collection for objective spectral
diagnoses. Serum ATR-FTIR spectroscopy involves no
sample preparation and is cost-effective due to the minimal
use of consumables (to remove the dried serum film from
IRE), thus it is a beneficial diagnostic tool with little
financial burden.
Rapid stratified serum diagnostics enables the diagnosis
of cancer depending on the information required by dif-
ferent multiple clinical settings from a single sample.
Using only 1 ll of human serum, a 433 patient dataset
(3897 spectra) and collecting spectra within 10 min from
serum application to the ATR crystal, we have success-
fully discriminated, for the first time, between cancer
versus non-cancer, cancer severity and the origin of
metastatic disease from serum with high sensitivities and
specificities. In addition, the feature extraction performed
has identified the salient spectral information, reduced
patient variance and allows for targeting the most dis-
criminatory regions during spectral collection, thus
reducing collection times. This research examines the
ability of feature extraction to improve diagnostic ability
by extracting discriminatory features of the original
spectral data. The proposed stratified diagnostic approach
has substantial and almost perfect inter-observer agree-
ment Kappa values, supporting the use of our diagnostic
models in a clinical setting. We believe the ability to
reduce the time to diagnosis based upon a relatively non-
invasive diagnostic test, with significant inter-observer
agreement and one that is capable of deployment across
clinical situations (dependent upon the diagnostic question
posed) would provide rapid patient entry to the clinical
process, profiling of at-risk population cohorts, as well as
enabling close clinical follow up throughout resulting in a
reduction in mortality and morbidity and increases
healthcare efficiency.
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